23,066,546 Shares in Boston Scientific Corporation $BSX Purchased by Norges Bank

Norges Bank purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 23,066,546 shares of the medical equipment provider’s stock, valued at approximately $2,199,395,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of BSX. Brighton Jones LLC grew its holdings in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares during the period. FWL Investment Management LLC bought a new position in Boston Scientific during the second quarter worth about $26,000. Main Street Financial Solutions LLC grew its holdings in Boston Scientific by 35.3% during the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after purchasing an additional 1,971 shares during the period. Ieq Capital LLC grew its holdings in Boston Scientific by 97.0% during the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after purchasing an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC grew its holdings in Boston Scientific by 56.2% during the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after purchasing an additional 2,556 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Cheryl Pegus purchased 1,770 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ? increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 9,800 shares of company stock worth $554,012. Company insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on BSX. Barclays reduced their price objective on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday. JPMorgan Chase & Co. reduced their price objective on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. TD Cowen reduced their price objective on Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Robert W. Baird set a $70.00 price objective on Boston Scientific in a report on Thursday. Finally, UBS Group reduced their price objective on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $87.46.

Boston Scientific Trading Down 1.6%

Shares of BSX stock opened at $48.32 on Friday. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The stock has a market cap of $71.82 billion, a P/E ratio of 20.22, a price-to-earnings-growth ratio of 0.90 and a beta of 0.62. The stock has a 50 day simple moving average of $60.23 and a 200 day simple moving average of $78.62. Boston Scientific Corporation has a 1 year low of $48.13 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts predict that Boston Scientific Corporation will post 3.37 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a stock repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight/hold and lowered its outlook on the stock, citing rising uncertainty around the company’s electrophysiology business and WATCHMAN growth. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Reuters reported Boston Scientific hit a two-year low after flagging weaker demand for its WATCHMAN heart device, adding to investor concern that a core growth driver is slowing. Boston Scientific hits two-year low after flagging weaker demand for heart device
• Negative Sentiment: The company’s 2026 guidance was reiterated, but investors viewed it as underwhelming given the slowdown in WATCHMAN and softer urology demand, which hurt sentiment further. Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance
• Negative Sentiment: Analyst commentary from Zacks said Boston Scientific and Abbott both posted solid growth, but Boston Scientific is facing mounting operational pressures, which may be limiting upside near term. BSX vs. ABT: Which Medical Stock Has More Upside Potential?
• Positive Sentiment: Despite the selloff, Boston Scientific’s clinical pipeline remains active, with updates on the FARAPULSE PFA atrial fibrillation study and a painful diabetic neuropathy trial milestone that could support future growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation Boston Scientific Nears Key Data Milestone in Painful Diabetic Neuropathy Trial
• Positive Sentiment: Unusually large call-option buying suggests some traders are positioning for a rebound in BSX after the recent weakness. Investors Buy Large Volume of Call Options on Boston Scientific (NYSE:BSX)

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.